Internal Med Medical News about Strongyloidiasis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prevention of strongyloides hyperinfection syndrome: A rheumatological point of view
European Journal of Internal Medicine , 11/09/09

Santiago M et al. – Since there is no evidence on the prophylaxis of SHS in immunosuppressed rheumatic patients, the suggested regimen for that prophylaxis may rely on the results obtained from therapeutical studies. Ivermectin has the best safety profile, lower cost and best efficacy and should be the drug of choice for the prophylaxis of SHS in such patients. Although a definitive prophylactic regimen has not been defined, the option for 200[micro]g/kg/day for 2days, repeated within 2weeks, seems to be a reasonable approach. Such regimen should be repeated every 6months in case of persisting immunosuppression in permanent residents of endemic areas.